Calithera to Present at the H.C. Wainwright Global Investment Conference
Calithera to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.
加利福尼亞州南舊金山，2022年5月17日(環球網)--臨牀階段、精確腫瘤學生物製藥公司卡里瑟拉生物科學公司(納斯達克代碼：CALA)今天宣佈，公司創始人、總裁兼首席執行官蘇珊·莫利諾博士將出席5月23-25日在佛羅裏達州邁阿密舉行的H.C.温賴特全球投資大會。
The presentation will be available for on-demand viewing starting Tuesday, May 24 at 7:00 a.m. Eastern Time, and can be accessed through the Investors section of the Company's website at . The replay of the webcast will be available on the Company's website for 30 days.
演示文稿將於5月24日(星期二)上午7：00開始提供點播觀看。東部時間，可通過公司網站的投資者部分訪問。網絡直播的重播將在公司網站上播放30天。
About Calithera
關於卡里瑟拉
Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.
卡利瑟拉生物科學公司是一家臨牀階段、精確的腫瘤學生物製藥公司，開發有針對性的治療方法，以重新定義生物標記物特定患者羣體的治療。在對嚴謹科學的承諾和對改善受癌症和其他危及生命的疾病影響的人們的生活的熱情的推動下，Calithera正在推進一系列強大的研究、小分子腫瘤化合物的管道，採用生物標記物驅動的方法，針對癌細胞中的遺傳脆弱性，為患有侵襲性血液病和實體瘤癌症的患者提供新的治療方法，目前這些患者的治療選擇有限。
Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit .
卡利瑟拉公司總部設在加利福尼亞州舊金山南部。欲瞭解更多關於卡利瑟拉的信息，請訪問。
Forward Looking Statements
前瞻性陳述
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera's product candidates, the overall advancement of Calithera's product candidates in preclinical development and clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera's plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
本新聞稿中包含的有關非歷史事實的陳述屬於“1995年私人證券訴訟改革法案”所指的“前瞻性陳述”。“可能”、“將”、“預期”、“預期”、“估計”、“打算”、“穩妥”等詞語和類似的表述(以及涉及未來事件、條件或情況的其他詞語或表述)旨在識別前瞻性表述。這些陳述包括與卡列瑟拉候選產品的安全性、耐受性和有效性、卡列瑟拉候選產品在臨牀前開發和臨牀試驗中的整體進步、晚期疾病患者的治療方面未得到滿足的需求以及卡列瑟拉繼續開發其候選產品的計劃有關的聲明。由於此類陳述受風險和不確定因素的影響，實際結果可能與此類前瞻性陳述所表達或暗示的結果大不相同。Calithera開發的潛在候選產品可能不會在預期的時間內或根本不能通過臨牀開發或獲得所需的監管批准。此外，臨牀試驗可能不能證實本新聞稿中描述或假定的任何安全性、有效性或其他產品特性。這樣的候選產品可能不會對患者有益，也可能不會成功商業化。如果未能達到上述任何事項的預期，可能會對卡利瑟拉的股票價格產生負面影響。有關影響卡利瑟拉公司業務的這些和其他風險因素的更多信息，可在卡利瑟拉公司提交給證券交易委員會的定期文件中找到，網址為www.sec.gov。這些前瞻性陳述不是對未來業績的保證，僅在本文發佈之日起發表，並且，除法律另有要求外, 卡利瑟拉公司沒有義務更新這些前瞻性陳述，以反映未來的事件或情況。
CONTACTS:
Stephanie Wong
Chief Financial Officer
650.870.1063
ir@Calithera.com
觸點:
斯蒂芬妮·王
首席財務官
650.870.1063
郵箱：ir@Calithera.com
INVESTORS:
Burns McClellan
Lee Roth
212.213.0006
lroth@burnsmc.com
投資者：
伯恩斯·麥克萊倫
李·羅斯
212.213.0006
郵箱：lroth@burnsmc.com
譯文內容由第三人軟體翻譯。